In parallel with the CUMS data, administration of paroxetine and oroxylin A notably ameliorated the CRS-induced decreasing effects on the protein levels of BDNF [ANOVA: CRS, F (1, 40) = 26.719, p < 0.01; Drug, F (3, 40) = 22.773, p < 0.01; Interaction, F (3, 40) = 18.675, p < 0.01], pTrkB [ANOVA: CRS, F (1, 40) = 30.149, p < 0.01; Drug, F (3, 40) = 21.665, p < 0.01; Interaction, F (3, 40) = 13.887, p < 0.01] and pCREB [ANOVA: CRS, F (1, 40) = 24.205, p < 0.01; Drug, F (3, 40) = 18.992, p < 0.01; Interaction, F (3, 40) = 12.639, p < 0.01] in the hippocampus (n = 6, p < 0.01). This evidence concerns the gene BDNF and congenital rubella syndrome.